-
1
-
-
32944469010
-
Changing paradigms-An update on the multidisciplinary management of malignant glioma
-
Stupp, R.; Hegi, M.E.; van den Bent, M.J.; Mason, W.P.; Weller, M.; Mirimanoff, R.O.; Cairncross, J.G. Changing paradigms-An update on the multidisciplinary management of malignant glioma. Oncologist 2006, 11, 165-180.
-
(2006)
Oncologist
, vol.11
, pp. 165-180
-
-
Stupp, R.1
Hegi, M.E.2
van den Bent, M.J.3
Mason, W.P.4
Weller, M.5
Mirimanoff, R.O.6
Cairncross, J.G.7
-
2
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses her2
-
Slamon, D.J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M. et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses her2. N. Engl. J. Med. 2001, 344, 783-792.
-
(2001)
N. Engl. J. Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
Fleming, T.7
Eiermann, W.8
Wolter, J.9
Pegram, M.10
-
3
-
-
60749137451
-
Beyond chemotherapy: Targeted therapies in ovarian cancer
-
Yap, T.A.; Carden, C.P.; Kaye, S.B. Beyond chemotherapy: Targeted therapies in ovarian cancer. Nat. Rev. Cancer 2009, 9, 167-181.
-
(2009)
Nat. Rev. Cancer
, vol.9
, pp. 167-181
-
-
Yap, T.A.1
Carden, C.P.2
Kaye, S.B.3
-
4
-
-
33947594043
-
Efficacy and safety of single-agent pertuzumab (rhumab 2c4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy
-
Agus, D.B.; Sweeney, C.J.; Morris, M.J.; Mendelson, D.S.; McNeel, D.G.; Ahmann, F.R.; Wang, J.; Derynck, M.K.; Ng, K.; Lyons, B. et al. Efficacy and safety of single-agent pertuzumab (rhumab 2c4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J. Clin. Oncol. 2007, 25, 675-681.
-
(2007)
J. Clin. Oncol
, vol.25
, pp. 675-681
-
-
Agus, D.B.1
Sweeney, C.J.2
Morris, M.J.3
Mendelson, D.S.4
McNeel, D.G.5
Ahmann, F.R.6
Wang, J.7
Derynck, M.K.8
Ng, K.9
Lyons, B.10
-
5
-
-
33845408544
-
Role of erlotinib in the management of pancreatic cancer
-
Starling, N.; Neoptolemos, J.; Cunningham, D. Role of erlotinib in the management of pancreatic cancer. Ther. Clin. Risk Manag. 2006, 2, 435-445.
-
(2006)
Ther. Clin. Risk Manag
, vol.2
, pp. 435-445
-
-
Starling, N.1
Neoptolemos, J.2
Cunningham, D.3
-
6
-
-
20144381957
-
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
-
Chung, K.Y.; Shia, J.; Kemeny, N.E.; Shah, M.; Schwartz, G.K.; Tse, A.; Hamilton, A.; Pan, D.; Schrag, D.; Schwartz, L. et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 2005, 23, 1803-1810.
-
(2005)
J. Clin. Oncol
, vol.23
, pp. 1803-1810
-
-
Chung, K.Y.1
Shia, J.2
Kemeny, N.E.3
Shah, M.4
Schwartz, G.K.5
Tse, A.6
Hamilton, A.7
Pan, D.8
Schrag, D.9
Schwartz, L.10
-
7
-
-
32144433159
-
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
-
Bonner, J.A.; Harari, P.M.; Giralt, J.; Azarnia, N.; Shin, D.M.; Cohen, R.B.; Jones, C.U.; Sur, R.; Raben, D.; Jassem, J. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Eng. J. Med. 2006, 354, 567-578.
-
(2006)
N. Eng. J. Med
, vol.354
, pp. 567-578
-
-
Bonner, J.A.1
Harari, P.M.2
Giralt, J.3
Azarnia, N.4
Shin, D.M.5
Cohen, R.B.6
Jones, C.U.7
Sur, R.8
Raben, D.9
Jassem, J.10
-
8
-
-
1342323632
-
Erbb receptors: Directing key signaling networks throughout life
-
Holbro, T.; Hynes, N.E. Erbb receptors: Directing key signaling networks throughout life. Annu. Rev. Pharmacol. Toxicol. 2004, 44, 195-217.
-
(2004)
Annu. Rev. Pharmacol. Toxicol
, vol.44
, pp. 195-217
-
-
Holbro, T.1
Hynes, N.E.2
-
9
-
-
0037429649
-
Neuregulins: Functions, forms, and signaling strategies
-
Falls, D.L. Neuregulins: Functions, forms, and signaling strategies. Exp. Cell Res. 2003, 284, 14-30.
-
(2003)
Exp. Cell Res
, vol.284
, pp. 14-30
-
-
Falls, D.L.1
-
10
-
-
0030919509
-
Neuregulins and their receptors: A versatile signaling module in organogenesis and oncogenesis
-
Burden, S.; Yarden, Y. Neuregulins and their receptors: A versatile signaling module in organogenesis and oncogenesis. Neuron 1997, 18, 847-855.
-
(1997)
Neuron
, vol.18
, pp. 847-855
-
-
Burden, S.1
Yarden, Y.2
-
11
-
-
1242315584
-
Signal transduction and oncogenesis by erbb/her receptors
-
Marmor, M.D.; Skaria, K.B.; Yarden, Y. Signal transduction and oncogenesis by erbb/her receptors. Int. J. Rad. Oncol. Biol. Phys. 2004, 58, 903-913.
-
(2004)
Int. J. Rad. Oncol. Biol. Phys
, vol.58
, pp. 903-913
-
-
Marmor, M.D.1
Skaria, K.B.2
Yarden, Y.3
-
12
-
-
0036784463
-
Trastuzumab-associated cardiotoxicity
-
Keefe, D.L. Trastuzumab-associated cardiotoxicity. Cancer 2002, 95, 1592-1600.
-
(2002)
Cancer
, vol.95
, pp. 1592-1600
-
-
Keefe, D.L.1
-
13
-
-
34247480545
-
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
-
Force, T.; Krause, D.S.; van Etten, R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 2007, 7, 332-344.
-
(2007)
Nat. Rev. Cancer
, vol.7
, pp. 332-344
-
-
Force, T.1
Krause, D.S.2
van Etten, R.A.3
-
14
-
-
0024497513
-
The limited reliability of physical signs for estimating hemodynamics in chronic heart failure
-
Stevenson, L.W.; Perloff, J.K. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. J. Am. Med. Assoc. 1989, 261, 884-888.
-
(1989)
J. Am. Med. Assoc
, vol.261
, pp. 884-888
-
-
Stevenson, L.W.1
Perloff, J.K.2
-
15
-
-
0031936410
-
Specificity within the egf family/erbb receptor family signaling network
-
Riese, D.J.; Stern, D.F. Specificity within the egf family/erbb receptor family signaling network. BioEssays 1998, 20, 41-48.
-
(1998)
BioEssays
, vol.20
, pp. 41-48
-
-
Riese, D.J.1
Stern, D.F.2
-
16
-
-
0035256698
-
Untangling the erbb signalling network
-
Yarden, Y.; Sliwkowski, M.X. Untangling the erbb signalling network. Nat. Rev. 2001, 2, 127-137.
-
(2001)
Nat. Rev
, vol.2
, pp. 127-137
-
-
Yarden, Y.1
Sliwkowski, M.X.2
-
17
-
-
0034773992
-
The egfr family and its ligands in human cancer: Signalling mechanisms and therapeutic opportunities
-
Yarden, Y. The egfr family and its ligands in human cancer: Signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 2001, 37 (Suppl. 4), S3-S8.
-
(2001)
Eur. J. Cancer
, vol.37
, Issue.SUPPL. 4
-
-
Yarden, Y.1
-
18
-
-
0042308353
-
The egf receptor family-Multiple roles in proliferation, differentiation, and neoplasia with an emphasis on her4
-
discussion 333-314
-
Earp, H.S.; Calvo, B.F.; Sartor, C.I. The egf receptor family-Multiple roles in proliferation, differentiation, and neoplasia with an emphasis on her4. Trans. Am. Clin. Climatol. Assoc. 2003, 114, 315-333; discussion 333-314.
-
(2003)
Trans. Am. Clin. Climatol. Assoc
, vol.114
, pp. 315-333
-
-
Earp, H.S.1
Calvo, B.F.2
Sartor, C.I.3
-
19
-
-
9444287030
-
Common and distinct elements in cellular signaling via egf and fgf receptors
-
Schlessinger, J. Common and distinct elements in cellular signaling via egf and fgf receptors. Science 2004, 306, 1506-1507.
-
(2004)
Science
, vol.306
, pp. 1506-1507
-
-
Schlessinger, J.1
-
20
-
-
0028884413
-
Requirement for neuregulin receptor erbb2 in neural and cardiac development
-
Lee, K.F.; Simon, H.; Chen, H.; Bates, B.; Hung, M.C.; Hauser, C. Requirement for neuregulin receptor erbb2 in neural and cardiac development. Nature 1995, 378, 394-398.
-
(1995)
Nature
, vol.378
, pp. 394-398
-
-
Lee, K.F.1
Simon, H.2
Chen, H.3
Bates, B.4
Hung, M.C.5
Hauser, C.6
-
21
-
-
0028785406
-
Aberrant neural and cardiac development in mice lacking the erbb4 neuregulin receptor
-
Gassmann, M.; Casagranda, F.; Orioli, D.; Simon, H.; Lai, C.; Klein, R.; Lemke, G. Aberrant neural and cardiac development in mice lacking the erbb4 neuregulin receptor. Nature 1995, 378, 390-394.
-
(1995)
Nature
, vol.378
, pp. 390-394
-
-
Gassmann, M.1
Casagranda, F.2
Orioli, D.3
Simon, H.4
Lai, C.5
Klein, R.6
Lemke, G.7
-
22
-
-
0028827104
-
Multiple essential functions of neuregulin in development
-
Meyer, D.; Birchmeier, C. Multiple essential functions of neuregulin in development. Nature 1995, 378, 386-390.
-
(1995)
Nature
, vol.378
, pp. 386-390
-
-
Meyer, D.1
Birchmeier, C.2
-
23
-
-
0031454062
-
Erbb3 is required for normal cerebellar and cardiac development: A comparison with erbb2-and heregulin-deficient mice
-
Erickson, S.L.; O'Shea, K.S.; Ghaboosi, N.; Loverro, L.; Frantz, G.; Bauer, M.; Lu, L.H.; Moore, M.W. Erbb3 is required for normal cerebellar and cardiac development: A comparison with erbb2-and heregulin-deficient mice. Development 1997, 124, 4999-5011.
-
(1997)
Development
, vol.124
, pp. 4999-5011
-
-
Erickson, S.L.1
O'Shea, K.S.2
Ghaboosi, N.3
Loverro, L.4
Frantz, G.5
Bauer, M.6
Lu, L.H.7
Moore, M.W.8
-
24
-
-
0029074587
-
Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor
-
Miettinen, P.J.; Berger, J.E.; Meneses, J.; Phung, Y.; Pedersen, R.A.; Werb, Z.; Derynck, R. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995, 376, 337-341.
-
(1995)
Nature
, vol.376
, pp. 337-341
-
-
Miettinen, P.J.1
Berger, J.E.2
Meneses, J.3
Phung, Y.4
Pedersen, R.A.5
Werb, Z.6
Derynck, R.7
-
25
-
-
0029045856
-
Strain-dependent epithelial defects in mice lacking the egf receptor
-
Sibilia, M.; Wagner, E.F. Strain-dependent epithelial defects in mice lacking the egf receptor. Science 1995, 269, 234-238.
-
(1995)
Science
, vol.269
, pp. 234-238
-
-
Sibilia, M.1
Wagner, E.F.2
-
26
-
-
0032562770
-
Neuregulins promote survival and growth of cardiac myocytes. Persistence of erbb2 and erbb4 expression in neonatal and adult ventricular myocytes
-
Zhao, Y.Y.; Sawyer, D.R.; Baliga, R.R.; Opel, D.J.; Han, X.; Marchionni, M.A.; Kelly, R.A. Neuregulins promote survival and growth of cardiac myocytes. Persistence of erbb2 and erbb4 expression in neonatal and adult ventricular myocytes. J. Biol. Chem. 1998, 273, 10261-10269.
-
(1998)
J. Biol. Chem
, vol.273
, pp. 10261-10269
-
-
Zhao, Y.Y.1
Sawyer, D.R.2
Baliga, R.R.3
Opel, D.J.4
Han, X.5
Marchionni, M.A.6
Kelly, R.A.7
-
27
-
-
0028955388
-
Epidermal growth factor-related peptides and their receptors in human malignancies
-
Salomon, D.S.; Brandt, R.; Ciardiello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 1995, 19, 183-232.
-
(1995)
Crit. Rev. Oncol. Hematol
, vol.19
, pp. 183-232
-
-
Salomon, D.S.1
Brandt, R.2
Ciardiello, F.3
Normanno, N.4
-
28
-
-
0026801871
-
Expression of egf, tgf-alpha and egfr in squamous cell lung carcinomas
-
Gorgoulis, V.; Aninos, D.; Mikou, P.; Kanavaros, P.; Karameris, A.; Joardanoglou, J.; Rasidakis, A.; Veslemes, M.; Ozanne, B.; Spandidos, D.A. Expression of egf, tgf-alpha and egfr in squamous cell lung carcinomas. Anticancer Res. 1992, 12, 1183-1187.
-
(1992)
Anticancer Res
, vol.12
, pp. 1183-1187
-
-
Gorgoulis, V.1
Aninos, D.2
Mikou, P.3
Kanavaros, P.4
Karameris, A.5
Joardanoglou, J.6
Rasidakis, A.7
Veslemes, M.8
Ozanne, B.9
Spandidos, D.A.10
-
29
-
-
0027524082
-
Oncogenes in head and neck cancer
-
Irish, J.C.; Bernstein, A. Oncogenes in head and neck cancer. Laryngoscope 1993, 103, 42-52.
-
(1993)
Laryngoscope
, vol.103
, pp. 42-52
-
-
Irish, J.C.1
Bernstein, A.2
-
30
-
-
0026521394
-
Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails
-
Ekstrand, A.J.; Sugawa, N.; James, C.D.; Collins, V.P. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. USA 1992, 89, 4309-4313.
-
(1992)
Proc. Natl. Acad. Sci. USA
, vol.89
, pp. 4309-4313
-
-
Ekstrand, A.J.1
Sugawa, N.2
James, C.D.3
Collins, V.P.4
-
31
-
-
0028800035
-
Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors
-
Moscatello, D.K.; Holgado-Madruga, M.; Godwin, A.K.; Ramirez, G.; Gunn, G.; Zoltick, P.W.; Biegel, J.A.; Hayes, R.L.; Wong, A.J. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 1995, 55, 5536-5539.
-
(1995)
Cancer Res
, vol.55
, pp. 5536-5539
-
-
Moscatello, D.K.1
Holgado-Madruga, M.2
Godwin, A.K.3
Ramirez, G.4
Gunn, G.5
Zoltick, P.W.6
Biegel, J.A.7
Hayes, R.L.8
Wong, A.J.9
-
32
-
-
0027074588
-
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of mcf-7 cells transfected with her2/neu
-
Benz, C.C.; Scott, G.K.; Sarup, J.C.; Johnson, R.M.; Tripathy, D.; Coronado, E.; Shepard, H.M.; Osborne, C.K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of mcf-7 cells transfected with her2/neu. Breast Cancer Res. Treat. 1992, 24, 85-95.
-
(1992)
Breast Cancer Res. Treat
, vol.24
, pp. 85-95
-
-
Benz, C.C.1
Scott, G.K.2
Sarup, J.C.3
Johnson, R.M.4
Tripathy, D.5
Coronado, E.6
Shepard, H.M.7
Osborne, C.K.8
-
33
-
-
16244415180
-
Constitutively active foxo4 inhibits akt activity, regulates p27 kip1 stability, and suppresses her2-mediated tumorigenicity
-
Yang, H.; Zhao, R.; Yang, H.Y.; Lee, M.H. Constitutively active foxo4 inhibits akt activity, regulates p27 kip1 stability, and suppresses her2-mediated tumorigenicity. Oncogene 2005, 24, 1924-1935.
-
(2005)
Oncogene
, vol.24
, pp. 1924-1935
-
-
Yang, H.1
Zhao, R.2
Yang, H.Y.3
Lee, M.H.4
-
34
-
-
0026085837
-
Erbb2 amplification in breast cancer with a high rate of proliferation
-
Borg, A.; Baldetorp, B.; Ferno, M.; Killander, D.; Olsson, H.; Sigurdsson, H. Erbb2 amplification in breast cancer with a high rate of proliferation. Oncogene 1991, 6, 137-143.
-
(1991)
Oncogene
, vol.6
, pp. 137-143
-
-
Borg, A.1
Baldetorp, B.2
Ferno, M.3
Killander, D.4
Olsson, H.5
Sigurdsson, H.6
-
35
-
-
26744476071
-
The biology of erbb-2/neu/her-2 and its role in cancer
-
Hynes, N.E.; Stern, D.F. The biology of erbb-2/neu/her-2 and its role in cancer. Biochim. Biophys. Acta 1994, 30, 2-3.
-
(1994)
Biochim. Biophys. Acta
, vol.30
, pp. 2-3
-
-
Hynes, N.E.1
Stern, D.F.2
-
36
-
-
4944232647
-
Lung cancer: Intragenic erbb2 kinase mutations in tumours
-
Stephens, P.; Hunter, C.; Bignell, G.; Edkins, S.; Davies, H.; Teague, J.; Stevens, C.; O'Meara, S.; Smith, R.; Parker, A. et al. Lung cancer: Intragenic erbb2 kinase mutations in tumours. Nature 2004, 431, 525-526.
-
(2004)
Nature
, vol.431
, pp. 525-526
-
-
Stephens, P.1
Hunter, C.2
Bignell, G.3
Edkins, S.4
Davies, H.5
Teague, J.6
Stevens, C.7
O'Meara, S.8
Smith, R.9
Parker, A.10
-
37
-
-
0042307325
-
The erbb2/erbb3 heterodimer functions as an oncogenic unit: Erbb2 requires erbb3 to drive breast tumor cell proliferation
-
Holbro, T.; Beerli, R.R.; Maurer, F.; Koziczak, M.; Barbas, C.F., III; Hynes, N.E. The erbb2/erbb3 heterodimer functions as an oncogenic unit: Erbb2 requires erbb3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 2003, 100, 8933-8938.
-
(2003)
Proc. Natl. Acad. Sci. USA
, vol.100
, pp. 8933-8938
-
-
Holbro, T.1
Beerli, R.R.2
Maurer, F.3
Koziczak, M.4
Barbas III, C.F.5
Hynes, N.E.6
-
38
-
-
0034053352
-
C-erbb-4 protein expression in human breast cancer
-
Kew, T.Y.; Bell, J.A.; Pinder, S.E.; Denley, H.; Srinivasan, R.; Gullick, W.J.; Nicholson, R.I.; Blamey, R.W.; Ellis, I.O. C-erbb-4 protein expression in human breast cancer. Br. J. Cancer 2000, 82, 1163-1170.
-
(2000)
Br. J. Cancer
, vol.82
, pp. 1163-1170
-
-
Kew, T.Y.1
Bell, J.A.2
Pinder, S.E.3
Denley, H.4
Srinivasan, R.5
Gullick, W.J.6
Nicholson, R.I.7
Blamey, R.W.8
Ellis, I.O.9
-
39
-
-
0030741967
-
Prognostic significance of her2 and her4 coexpression in childhood medulloblastoma
-
Gilbertson, R.J.; Perry, R.H.; Kelly, P.J.; Pearson, A.D.; Lunec, J. Prognostic significance of her2 and her4 coexpression in childhood medulloblastoma. Cancer Res. 1997, 57, 3272-3280.
-
(1997)
Cancer Res
, vol.57
, pp. 3272-3280
-
-
Gilbertson, R.J.1
Perry, R.H.2
Kelly, P.J.3
Pearson, A.D.4
Lunec, J.5
-
40
-
-
30744432128
-
Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies
-
Iannello, A.; Ahmad, A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev. 2005, 24, 487-499.
-
(2005)
Cancer Metastasis Rev
, vol.24
, pp. 487-499
-
-
Iannello, A.1
Ahmad, A.2
-
41
-
-
33747855481
-
Comparing antibody and small-molecule therapies for cancer
-
Imai, K.; Takaoka, A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 2006, 6, 714-727.
-
(2006)
Nat. Rev. Cancer
, vol.6
, pp. 714-727
-
-
Imai, K.1
Takaoka, A.2
-
42
-
-
33646352962
-
Potent antibody therapeutics by design
-
Carter, P.J. Potent antibody therapeutics by design. Nat. Rev. Immunol. 2006, 6, 343-357.
-
(2006)
Nat. Rev. Immunol
, vol.6
, pp. 343-357
-
-
Carter, P.J.1
-
43
-
-
0037392444
-
Issues and progress with protein kinase inhibitors for cancer treatment
-
Dancey, J.; Sausville, E.A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov. 2003, 2, 296-313.
-
(2003)
Nat. Rev. Drug Discov
, vol.2
, pp. 296-313
-
-
Dancey, J.1
Sausville, E.A.2
-
44
-
-
3442891161
-
Dual-agent molecular targeting of the epidermal growth factor receptor (egfr): Combining anti-egfr antibody with tyrosine kinase inhibitor
-
Huang, S.; Armstrong, E.A.; Benavente, S.; Chinnaiyan, P.; Harari, P.M. Dual-agent molecular targeting of the epidermal growth factor receptor (egfr): Combining anti-egfr antibody with tyrosine kinase inhibitor. Cancer Res. 2004, 64, 5355-5362.
-
(2004)
Cancer Res
, vol.64
, pp. 5355-5362
-
-
Huang, S.1
Armstrong, E.A.2
Benavente, S.3
Chinnaiyan, P.4
Harari, P.M.5
-
45
-
-
33750964250
-
Terminal ballistics of kinase inhibitors: There are no magic bullets
-
Maitland, M.L.; Ratain, M.J. Terminal ballistics of kinase inhibitors: There are no magic bullets. Ann. Intern. Med. 2006, 145, 702-703.
-
(2006)
Ann. Intern. Med
, vol.145
, pp. 702-703
-
-
Maitland, M.L.1
Ratain, M.J.2
-
46
-
-
77955865478
-
Why do kinase inhibitors cause cardiotoxicity and what can be done about it?
-
Cheng, H.; Force, T. Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog. Cardiovas. Dis. 2010, 53, 114-120.
-
(2010)
Prog. Cardiovas. Dis
, vol.53
, pp. 114-120
-
-
Cheng, H.1
Force, T.2
-
47
-
-
0034779291
-
The egfr as a target for anticancer therapy-Focus on cetuximab
-
Baselga, J. The egfr as a target for anticancer therapy-Focus on cetuximab. Eur. J. Cancer 2001, 37, S16-S22.
-
(2001)
Eur. J. Cancer
, vol.37
-
-
Baselga, J.1
-
49
-
-
17444403242
-
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
-
Li, S.; Schmitz, K.R.; Jeffrey, P.D.; Wiltzius, J.J.; Kussie, P.; Ferguson, K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005, 7, 301-311.
-
(2005)
Cancer Cell
, vol.7
, pp. 301-311
-
-
Li, S.1
Schmitz, K.R.2
Jeffrey, P.D.3
Wiltzius, J.J.4
Kussie, P.5
Ferguson, K.M.6
-
50
-
-
10344239413
-
Gefitinib [mdash] a novel targeted approach to treating cancer
-
Herbst, R.S.; Fukuoka, M.; Baselga, J. Gefitinib [mdash] a novel targeted approach to treating cancer. Nat. Rev. Cancer 2004, 4, 979-987.
-
(2004)
Nat. Rev. Cancer
, vol.4
, pp. 979-987
-
-
Herbst, R.S.1
Fukuoka, M.2
Baselga, J.3
-
52
-
-
84866729833
-
Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (gc) and gemcitabine with erlotinib (ge) in unresectable pancreatic cancer
-
Jeon, E.K.; Won, H.S.; Ko, Y.H.; Lee, I.S.; Hong, T.H.; You, Y.K.; Lee, M.A. Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (gc) and gemcitabine with erlotinib (ge) in unresectable pancreatic cancer. J. Cancer Res. Clin. Oncol. 2012, 138, 1625-1630.
-
(2012)
J. Cancer Res. Clin. Oncol
, vol.138
, pp. 1625-1630
-
-
Jeon, E.K.1
Won, H.S.2
Ko, Y.H.3
Lee, I.S.4
Hong, T.H.5
You, Y.K.6
Lee, M.A.7
-
53
-
-
30544450275
-
Combining lapatinib (gw572016), a small molecule inhibitor of erbb1 and erbb2 tyrosine kinases, with therapeutic anti-erbb2 antibodies enhances apoptosis of erbb2-overexpressing breast cancer cells
-
Xia, W.; Gerard, C.M.; Liu, L.; Baudson, N.M.; Ory, T.L.; Spector, N.L. Combining lapatinib (gw572016), a small molecule inhibitor of erbb1 and erbb2 tyrosine kinases, with therapeutic anti-erbb2 antibodies enhances apoptosis of erbb2-overexpressing breast cancer cells. Oncogene 2005, 24, 6213-6221.
-
(2005)
Oncogene
, vol.24
, pp. 6213-6221
-
-
Xia, W.1
Gerard, C.M.2
Liu, L.3
Baudson, N.M.4
Ory, T.L.5
Spector, N.L.6
-
54
-
-
47649128339
-
Acute and fatal diarrhoea after erlotinib plus abdominal palliative hypofractionated radiotherapy in a metastatic non-small cell lung cancer patient: A case report
-
Silvano, G.; Lazzari, G.; Lovecchio, M.; Palazzo, C. Acute and fatal diarrhoea after erlotinib plus abdominal palliative hypofractionated radiotherapy in a metastatic non-small cell lung cancer patient: A case report. Lung Cancer 2008, 61, 270-273.
-
(2008)
Lung Cancer
, vol.61
, pp. 270-273
-
-
Silvano, G.1
Lazzari, G.2
Lovecchio, M.3
Palazzo, C.4
-
55
-
-
0037431759
-
Severe acute interstitial pneumonia and gefitinib
-
Inoue, A.; Saijo, Y.; Maemondo, M.; Gomi, K.; Tokue, Y.; Kimura, Y.; Ebina, M.; Kikuchi, T.; Moriya, T.; Nukiwa, T. Severe acute interstitial pneumonia and gefitinib. Lancet 2003, 361, 137-139.
-
(2003)
Lancet
, vol.361
, pp. 137-139
-
-
Inoue, A.1
Saijo, Y.2
Maemondo, M.3
Gomi, K.4
Tokue, Y.5
Kimura, Y.6
Ebina, M.7
Kikuchi, T.8
Moriya, T.9
Nukiwa, T.10
-
56
-
-
50949132320
-
Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics
-
Chen, M.H.; Kerkela, R.; Force, T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008, 118, 84-95.
-
(2008)
Circulation
, vol.118
, pp. 84-95
-
-
Chen, M.H.1
Kerkela, R.2
Force, T.3
-
57
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the her-2/neu oncogene
-
Slamon, D.J.; Clark, G.M.; Wong, S.G.; Levin, W.J.; Ullrich, A.; McGuire, W.L. Human breast cancer: Correlation of relapse and survival with amplification of the her-2/neu oncogene. Science 1987, 235, 177-182.
-
(1987)
Science
, vol.235
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
Levin, W.J.4
Ullrich, A.5
McGuire, W.L.6
-
58
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable her2-positive breast cancer
-
Romond, E.H.; Perez, E.A.; Bryant, J.; Suman, V.J.; Geyer, C.E.; Davidson, N.E.; Tan-Chiu, E.; Martino, S.; Paik, S.; Kaufman, P.A. et al. Trastuzumab plus adjuvant chemotherapy for operable her2-positive breast cancer. N. Eng. J. Med. 2005, 353, 1673-1684.
-
(2005)
N. Eng. J. Med
, vol.353
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
Suman, V.J.4
Geyer, C.E.5
Davidson, N.E.6
Tan-Chiu, E.7
Martino, S.8
Paik, S.9
Kaufman, P.A.10
-
59
-
-
46149111250
-
Trastuzumab in the adjuvant treatment of early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials
-
Dahabreh, I.J.; Linardou, H.; Siannis, F.; Fountzilas, G.; Murray, S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials. Oncologist 2008, 13, 620-630.
-
(2008)
Oncologist
, vol.13
, pp. 620-630
-
-
Dahabreh, I.J.1
Linardou, H.2
Siannis, F.3
Fountzilas, G.4
Murray, S.5
-
60
-
-
33344478381
-
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
-
Joensuu, H.; Kellokumpu-Lehtinen, P.L.; Bono, P.; Alanko, T.; Kataja, V.; Asola, R.; Utriainen, T.; Kokko, R.; Hemminki, A.; Tarkkanen, M. et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 2006, 354, 809-820.
-
(2006)
N. Engl. J. Med
, vol.354
, pp. 809-820
-
-
Joensuu, H.1
Kellokumpu-Lehtinen, P.L.2
Bono, P.3
Alanko, T.4
Kataja, V.5
Asola, R.6
Utriainen, T.7
Kokko, R.8
Hemminki, A.9
Tarkkanen, M.10
-
61
-
-
34347395733
-
Trastuzumab-Mechanism of action and use in clinical practice
-
Hudis, C.A. Trastuzumab-Mechanism of action and use in clinical practice. N. Engl. J. Med. 2007, 357, 39-51.
-
(2007)
N. Engl. J. Med
, vol.357
, pp. 39-51
-
-
Hudis, C.A.1
-
62
-
-
84865699475
-
Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays
-
Golay, J.; Introna, M. Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays. Arch. Biochem. Biophys. 2012, 526, 146-153.
-
(2012)
Arch. Biochem. Biophys
, vol.526
, pp. 146-153
-
-
Golay, J.1
Introna, M.2
-
63
-
-
0037291226
-
The crystal structure of a truncated erbb2 ectodomain reveals an active conformation, poised to interact with other erbb receptors
-
Garrett, T.P.J.; McKern, N.M.; Lou, M.; Elleman, T.C.; Adams, T.E.; Lovrecz, G.O.; Kofler, M.; Jorissen, R.N.; Nice, E.C.; Burgess, A.W. et al. The crystal structure of a truncated erbb2 ectodomain reveals an active conformation, poised to interact with other erbb receptors. Mol. Cell 2003, 11, 495-505.
-
(2003)
Mol. Cell
, vol.11
, pp. 495-505
-
-
Garrett, T.P.J.1
McKern, N.M.2
Lou, M.3
Elleman, T.C.4
Adams, T.E.5
Lovrecz, G.O.6
Kofler, M.7
Jorissen, R.N.8
Nice, E.C.9
Burgess, A.W.10
-
64
-
-
0035874981
-
Trastuzumab (herceptin), a humanized anti-her2 receptor monoclonal antibody, inhibits basal and activated her2 ectodomain cleavage in breast cancer cells
-
Molina, M.A.; Codony-Servat, J.; Albanell, J.; Rojo, F.; Arribas, J.; Baselga, J. Trastuzumab (herceptin), a humanized anti-her2 receptor monoclonal antibody, inhibits basal and activated her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001, 61, 4744-4749.
-
(2001)
Cancer Res
, vol.61
, pp. 4744-4749
-
-
Molina, M.A.1
Codony-Servat, J.2
Albanell, J.3
Rojo, F.4
Arribas, J.5
Baselga, J.6
-
65
-
-
0032532950
-
Nh2-terminally truncated her-2/neu protein: Relationship with shedding of the extracellular domain and with prognostic factors in breast cancer
-
Christianson, T.A.; Doherty, J.K.; Lin, Y.J.; Ramsey, E.E.; Holmes, R.; Keenan, E.J.; Clinton, G.M. Nh2-terminally truncated her-2/neu protein: Relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res. 1998, 58, 5123-5129.
-
(1998)
Cancer Res
, vol.58
, pp. 5123-5129
-
-
Christianson, T.A.1
Doherty, J.K.2
Lin, Y.J.3
Ramsey, E.E.4
Holmes, R.5
Keenan, E.J.6
Clinton, G.M.7
-
66
-
-
0032885461
-
Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against lfa-3 and her2/neu
-
Cooley, S.; Burns, L.J.; Repka, T.; Miller, J.S. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against lfa-3 and her2/neu. Exp. Hematol. 1999, 27, 1533-1541.
-
(1999)
Exp. Hematol
, vol.27
, pp. 1533-1541
-
-
Cooley, S.1
Burns, L.J.2
Repka, T.3
Miller, J.S.4
-
67
-
-
0034076307
-
Inhibitory fc receptors modulate in vivo cytotoxicity against tumor targets
-
Clynes, R.A.; Towers, T.L.; Presta, L.G.; Ravetch, J.V. Inhibitory fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 2000, 6, 443-446.
-
(2000)
Nat. Med
, vol.6
, pp. 443-446
-
-
Clynes, R.A.1
Towers, T.L.2
Presta, L.G.3
Ravetch, J.V.4
-
68
-
-
51149117030
-
Drug insight: Intracellular inhibitors of her2[mdash]clinical development of lapatinib in breast cancer
-
Cameron, D.A.; Stein, S. Drug insight: Intracellular inhibitors of her2[mdash]clinical development of lapatinib in breast cancer. Nat. Clin. Prac. Oncol. 2008, 5, 512-520.
-
(2008)
Nat. Clin. Prac. Oncol
, vol.5
, pp. 512-520
-
-
Cameron, D.A.1
Stein, S.2
-
69
-
-
84866552915
-
Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: A meta-analysis of randomized evidence
-
Valachis, A.; Nearchou, A.; Lind, P.; Mauri, D. Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: A meta-analysis of randomized evidence. Breast Cancer Res. Treat. 2012, 135, 655-662.
-
(2012)
Breast Cancer Res. Treat
, vol.135
, pp. 655-662
-
-
Valachis, A.1
Nearchou, A.2
Lind, P.3
Mauri, D.4
-
70
-
-
84857236823
-
Lapatinib with trastuzumab for her2-positive early breast cancer (neoaltto): A randomised, open-label, multicentre, phase 3 trial
-
Baselga, J.; Bradbury, I.; Eidtmann, H.; Di Cosimo, S.; de Azambuja, E.; Aura, C.; Gomez, H.; Dinh, P.; Fauria, K.; van Dooren, V. et al. Lapatinib with trastuzumab for her2-positive early breast cancer (neoaltto): A randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379, 633-640.
-
(2012)
Lancet
, vol.379
, pp. 633-640
-
-
Baselga, J.1
Bradbury, I.2
Eidtmann, H.3
Di Cosimo, S.4
de Azambuja, E.5
Aura, C.6
Gomez, H.7
Dinh, P.8
Fauria, K.9
van Dooren, V.10
-
71
-
-
0035553174
-
The effects of the novel, reversible epidermal growth factor receptor/erbb-2 tyrosine kinase inhibitor, gw2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo
-
Rusnak, D.W.; Lackey, K.; Affleck, K.; Wood, E.R.; Alligood, K.J.; Rhodes, N.; Keith, B.R.; Murray, D.M.; Knight, W.B.; Mullin, R.J. et al. The effects of the novel, reversible epidermal growth factor receptor/erbb-2 tyrosine kinase inhibitor, gw2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 2001, 1, 85-94.
-
(2001)
Mol. Cancer Ther
, vol.1
, pp. 85-94
-
-
Rusnak, D.W.1
Lackey, K.2
Affleck, K.3
Wood, E.R.4
Alligood, K.J.5
Rhodes, N.6
Keith, B.R.7
Murray, D.M.8
Knight, W.B.9
Mullin, R.J.10
-
72
-
-
84860003304
-
Lapatinib distribution in her2 overexpressing experimental brain metastases of breast cancer
-
Taskar, K.S.; Rudraraju, V.; Mittapalli, R.K.; Samala, R.; Thorsheim, H.R.; Lockman, J.; Gril, B.; Hua, E.; Palmieri, D.; Polli, J.W. et al. Lapatinib distribution in her2 overexpressing experimental brain metastases of breast cancer. Pharm. Res. 2012, 29, 770-781.
-
(2012)
Pharm. Res
, vol.29
, pp. 770-781
-
-
Taskar, K.S.1
Rudraraju, V.2
Mittapalli, R.K.3
Samala, R.4
Thorsheim, H.R.5
Lockman, J.6
Gril, B.7
Hua, E.8
Palmieri, D.9
Polli, J.W.10
-
73
-
-
84874640697
-
New insights and emerging therapies for breast cancer brain metastases
-
Lim, E.; Lin, N.U. New insights and emerging therapies for breast cancer brain metastases. Oncology 2012, 26, 652-659, 663.
-
(2012)
Oncology
, vol.26
-
-
Lim, E.1
Lin, N.U.2
-
74
-
-
19044380618
-
Targeting ligand-activated erbb2 signaling inhibits breast and prostate tumor growth
-
Agus, D.B.; Akita, R.W.; Fox, W.D.; Lewis, G.D.; Higgins, B.; Pisacane, P.I.; Lofgren, J.A.; Tindell, C.; Evans, D.P.; Maiese, K. et al. Targeting ligand-activated erbb2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002, 2, 127-137.
-
(2002)
Cancer Cell
, vol.2
, pp. 127-137
-
-
Agus, D.B.1
Akita, R.W.2
Fox, W.D.3
Lewis, G.D.4
Higgins, B.5
Pisacane, P.I.6
Lofgren, J.A.7
Tindell, C.8
Evans, D.P.9
Maiese, K.10
-
75
-
-
33749003463
-
Clinical activity of pertuzumab (rhumab 2c4), a her dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor her2 activation status
-
Gordon, M.S.; Matei, D.; Aghajanian, C.; Matulonis, U.A.; Brewer, M.; Fleming, G.F.; Hainsworth, J.D.; Garcia, A.A.; Pegram, M.D.; Schilder, R.J. et al. Clinical activity of pertuzumab (rhumab 2c4), a her dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor her2 activation status. J. Clin. Oncol. 2006, 24, 4324-4332.
-
(2006)
J. Clin. Oncol
, vol.24
, pp. 4324-4332
-
-
Gordon, M.S.1
Matei, D.2
Aghajanian, C.3
Matulonis, U.A.4
Brewer, M.5
Fleming, G.F.6
Hainsworth, J.D.7
Garcia, A.A.8
Pegram, M.D.9
Schilder, R.J.10
-
76
-
-
77949901499
-
Open-label, phase ii, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer
-
Gianni, L.; Llado, A.; Bianchi, G.; Cortes, J.; Kellokumpu-Lehtinen, P.L.; Cameron, D.A.; Miles, D.; Salvagni, S.; Wardley, A.; Goeminne, J.C. et al. Open-label, phase ii, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 2010, 28, 1131-1137.
-
(2010)
J. Clin. Oncol
, vol.28
, pp. 1131-1137
-
-
Gianni, L.1
Llado, A.2
Bianchi, G.3
Cortes, J.4
Kellokumpu-Lehtinen, P.L.5
Cameron, D.A.6
Miles, D.7
Salvagni, S.8
Wardley, A.9
Goeminne, J.C.10
-
77
-
-
33846927744
-
Open-label phase ii study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer
-
De Bono, J.S.; Bellmunt, J.; Attard, G.; Droz, J.P.; Miller, K.; Flechon, A.; Sternberg, C.; Parker, C.; Zugmaier, G.; Hersberger-Gimenez, V. et al. Open-label phase ii study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J. Clin. Oncol. 2007, 25, 257-262.
-
(2007)
J. Clin. Oncol
, vol.25
, pp. 257-262
-
-
de Bono, J.S.1
Bellmunt, J.2
Attard, G.3
Droz, J.P.4
Miller, K.5
Flechon, A.6
Sternberg, C.7
Parker, C.8
Zugmaier, G.9
Hersberger-Gimenez, V.10
-
78
-
-
35949004420
-
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer
-
Herbst, R.S.; Davies, A.M.; Natale, R.B.; Dang, T.P.; Schiller, J.H.; Garland, L.L.; Miller, V.A.; Mendelson, D.; van den Abbeele, A.D.; Melenevsky, Y. et al. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin. Cancer Res. 2007, 13, 6175-6181.
-
(2007)
Clin. Cancer Res
, vol.13
, pp. 6175-6181
-
-
Herbst, R.S.1
Davies, A.M.2
Natale, R.B.3
Dang, T.P.4
Schiller, J.H.5
Garland, L.L.6
Miller, V.A.7
Mendelson, D.8
van den Abbeele, A.D.9
Melenevsky, Y.10
-
79
-
-
0037434791
-
Structure of the extracellular region of her2 alone and in complex with the herceptin fab
-
Cho, H.S.; Mason, K.; Ramyar, K.X.; Stanley, A.M.; Gabelli, S.B.; Denney, D.W., Jr.; Leahy, D.J. Structure of the extracellular region of her2 alone and in complex with the herceptin fab. Nature 2003, 421, 756-760.
-
(2003)
Nature
, vol.421
, pp. 756-760
-
-
Cho, H.S.1
Mason, K.2
Ramyar, K.X.3
Stanley, A.M.4
Gabelli, S.B.5
Denney Jr., D.W.6
Leahy, D.J.7
-
80
-
-
1842605531
-
Insights into erbb signaling from the structure of the erbb2-pertuzumab complex
-
Franklin, M.C.; Carey, K.D.; Vajdos, F.F.; Leahy, D.J.; de Vos, A.M.; Sliwkowski, M.X. Insights into erbb signaling from the structure of the erbb2-pertuzumab complex. Cancer Cell 2004, 5, 317-328.
-
(2004)
Cancer Cell
, vol.5
, pp. 317-328
-
-
Franklin, M.C.1
Carey, K.D.2
Vajdos, F.F.3
Leahy, D.J.4
de Vos, A.M.5
Sliwkowski, M.X.6
-
81
-
-
84855297353
-
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early her2-positive breast cancer (neosphere): A randomised multicentre, open-label, phase 2 trial
-
Gianni, L.; Pienkowski, T.; Im, Y.H.; Roman, L.; Tseng, L.M.; Liu, M.C.; Lluch, A.; Staroslawska, E.; de la Haba-Rodriguez, J.; Im, S.A. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early her2-positive breast cancer (neosphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012, 13, 25-32.
-
(2012)
Lancet Oncol
, vol.13
, pp. 25-32
-
-
Gianni, L.1
Pienkowski, T.2
Im, Y.H.3
Roman, L.4
Tseng, L.M.5
Liu, M.C.6
Lluch, A.7
Staroslawska, E.8
de la Haba-Rodriguez, J.9
Im, S.A.10
-
82
-
-
84862914692
-
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
-
Baselga, J.; Cortes, J.; Kim, S.B.; Im, S.A.; Hegg, R.; Im, Y.H.; Roman, L.; Pedrini, J.L.; Pienkowski, T.; Knott, A. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 2012, 366, 109-119.
-
(2012)
N. Engl. J. Med
, vol.366
, pp. 109-119
-
-
Baselga, J.1
Cortes, J.2
Kim, S.B.3
Im, S.A.4
Hegg, R.5
Im, Y.H.6
Roman, L.7
Pedrini, J.L.8
Pienkowski, T.9
Knott, A.10
-
83
-
-
33745805840
-
Role of neuregulin-1/erbb2 signaling in endothelium-cardiomyocyte cross-talk
-
Lemmens, K.; Segers, V.F.; Demolder, M.; de Keulenaer, G.W. Role of neuregulin-1/erbb2 signaling in endothelium-cardiomyocyte cross-talk. J. Biol. Chem. 2006, 281, 19469-19477.
-
(2006)
J. Biol. Chem
, vol.281
, pp. 19469-19477
-
-
Lemmens, K.1
Segers, V.F.2
Demolder, M.3
de Keulenaer, G.W.4
-
84
-
-
67650569135
-
Neuregulin1/erbb4 signaling induces cardiomyocyte proliferation and repair of heart injury
-
Bersell, K.; Arab, S.; Haring, B.; Kühn, B. Neuregulin1/erbb4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 2009, 138, 257-270.
-
(2009)
Cell
, vol.138
, pp. 257-270
-
-
Bersell, K.1
Arab, S.2
Haring, B.3
Kühn, B.4
-
85
-
-
33746048823
-
Neuregulin activates erbb2-dependent src/fak signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes
-
Kuramochi, Y.; Guo, X.; Sawyer, D.B. Neuregulin activates erbb2-dependent src/fak signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J. Mol. Cell. Cardiol. 2006, 41, 228-235.
-
(2006)
J. Mol. Cell. Cardiol
, vol.41
, pp. 228-235
-
-
Kuramochi, Y.1
Guo, X.2
Sawyer, D.B.3
-
86
-
-
0033393696
-
Neuregulin activation of erbb receptors in vascular endothelium leads to angiogenesis
-
Russell, K.S.; Stern, D.F.; Polverini, P.J.; Bender, J.R. Neuregulin activation of erbb receptors in vascular endothelium leads to angiogenesis. Am. J. Physiol. 1999, 277, H2205-H2211.
-
(1999)
Am. J. Physiol
, vol.277
-
-
Russell, K.S.1
Stern, D.F.2
Polverini, P.J.3
Bender, J.R.4
-
87
-
-
1642458136
-
Neuregulin-1 induces a negative inotropic effect in cardiac muscle: Role of nitric oxide synthase
-
Lemmens, K.; Fransen, P.; Sys, S.U.; Brutsaert, D.L.; de Keulenaer, G.W. Neuregulin-1 induces a negative inotropic effect in cardiac muscle: Role of nitric oxide synthase. Circulation 2004, 109, 324-326.
-
(2004)
Circulation
, vol.109
, pp. 324-326
-
-
Lemmens, K.1
Fransen, P.2
Sys, S.U.3
Brutsaert, D.L.4
de Keulenaer, G.W.5
-
88
-
-
74049164266
-
The vulnerability of the heart as a pluricellular paracrine organ: Lessons from unexpected triggers of heart failure in targeted erbb2 anticancer therapy
-
De Keulenaer, G.W.; Doggen, K.; Lemmens, K. The vulnerability of the heart as a pluricellular paracrine organ: Lessons from unexpected triggers of heart failure in targeted erbb2 anticancer therapy. Circ. Res. 2010, 106, 35-46.
-
(2010)
Circ. Res
, vol.106
, pp. 35-46
-
-
de Keulenaer, G.W.1
Doggen, K.2
Lemmens, K.3
-
89
-
-
0036498781
-
Cardiac dysfunction in the trastuzumab clinical trials experience
-
Seidman, A.; Hudis, C.; Pierri, M.K.; Shak, S.; Paton, V.; Ashby, M.; Murphy, M.; Stewart, S.J.; Keefe, D. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. 2002, 20, 1215-1221.
-
(2002)
J. Clin. Oncol
, vol.20
, pp. 1215-1221
-
-
Seidman, A.1
Hudis, C.2
Pierri, M.K.3
Shak, S.4
Paton, V.5
Ashby, M.6
Murphy, M.7
Stewart, S.J.8
Keefe, D.9
-
90
-
-
32144448027
-
Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment
-
Ewer, M.S.; Vooletich, M.T.; Durand, J.B.; Woods, M.L.; Davis, J.R.; Valero, V.; Lenihan, D.J. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J. Clin. Oncol. 2005, 23, 7820-7826.
-
(2005)
J. Clin. Oncol
, vol.23
, pp. 7820-7826
-
-
Ewer, M.S.1
Vooletich, M.T.2
Durand, J.B.3
Woods, M.L.4
Davis, J.R.5
Valero, V.6
Lenihan, D.J.7
-
91
-
-
77955906955
-
Mechanisms of anthracycline cardiac injury: Can we identify strategies for cardioprotection
-
Sawyer, D.B.; Peng, X.; Chen, B.; Pentassuglia, L.; Lim, C.C. Mechanisms of anthracycline cardiac injury: Can we identify strategies for cardioprotection? Prog. Cardiovasc. Dis. 2010, 53, 105-113.
-
(2010)
Prog. Cardiovasc. Dis
, vol.53
, pp. 105-113
-
-
Sawyer, D.B.1
Peng, X.2
Chen, B.3
Pentassuglia, L.4
Lim, C.C.5
-
92
-
-
84860523994
-
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
-
Octavia, Y.; Tocchetti, C.G.; Gabrielson, K.L.; Janssens, S.; Crijns, H.J.; Moens, A.L. Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. J. Mol. Cell. Cardiol. 2012, 52, 1213-1225.
-
(2012)
J. Mol. Cell. Cardiol
, vol.52
, pp. 1213-1225
-
-
Octavia, Y.1
Tocchetti, C.G.2
Gabrielson, K.L.3
Janssens, S.4
Crijns, H.J.5
Moens, A.L.6
-
93
-
-
49249135889
-
Anthracycline cardiotoxicity: From bench to bedside
-
Gianni, L.; Herman, E.H.; Lipshultz, S.E.; Minotti, G.; Sarvazyan, N.; Sawyer, D.B. Anthracycline cardiotoxicity: From bench to bedside. J. Clin. Oncol. 2008, 26, 3777-3784.
-
(2008)
J. Clin. Oncol
, vol.26
, pp. 3777-3784
-
-
Gianni, L.1
Herman, E.H.2
Lipshultz, S.E.3
Minotti, G.4
Sarvazyan, N.5
Sawyer, D.B.6
-
94
-
-
23944476155
-
Phase i safety, pharmacokinetics, and clinical activity study of lapatinib (gw572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
-
Burris, H.A., III; Hurwitz, H.I.; Dees, E.C.; Dowlati, A.; Blackwell, K.L.; O'Neil, B.; Marcom, P.K.; Ellis, M.J.; Overmoyer, B.; Jones, S.F. et al. Phase i safety, pharmacokinetics, and clinical activity study of lapatinib (gw572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. 2005, 23, 5305-5313.
-
(2005)
J. Clin. Oncol
, vol.23
, pp. 5305-5313
-
-
Burris III, H.A.1
Hurwitz, H.I.2
Dees, E.C.3
Dowlati, A.4
Blackwell, K.L.5
O'Neil, B.6
Marcom, P.K.7
Ellis, M.J.8
Overmoyer, B.9
Jones, S.F.10
-
95
-
-
33845886440
-
Lapatinib plus capecitabine for her2-positive advanced breast cancer
-
Geyer, C.E.; Forster, J.; Lindquist, D.; Chan, S.; Romieu, C.G.; Pienkowski, T.; Jagiello-Gruszfeld, A.; Crown, J.; Chan, A.; Kaufman, B. et al. Lapatinib plus capecitabine for her2-positive advanced breast cancer. N. Engl. J. Med. 2006, 355, 2733-2743.
-
(2006)
N. Engl. J. Med
, vol.355
, pp. 2733-2743
-
-
Geyer, C.E.1
Forster, J.2
Lindquist, D.3
Chan, S.4
Romieu, C.G.5
Pienkowski, T.6
Jagiello-Gruszfeld, A.7
Crown, J.8
Chan, A.9
Kaufman, B.10
-
96
-
-
67349248085
-
Cardiac toxicity with anti-her-2 therapies-what have we learned so far?
-
De Azambuja, E.; Bedard, P.; Suter, T.; Piccart-Gebhart, M. Cardiac toxicity with anti-her-2 therapies-what have we learned so far? Target. Oncol. 2009, 4, 77-88.
-
(2009)
Target. Oncol
, vol.4
, pp. 77-88
-
-
de Azambuja, E.1
Bedard, P.2
Suter, T.3
Piccart-Gebhart, M.4
-
97
-
-
0032851961
-
Nonclinical studies addressing the mechanism of action of trastuzumab (herceptin)
-
Sliwkowski, M.X.; Lofgren, J.A.; Lewis, G.D.; Hotaling, T.E.; Fendly, B.M.; Fox, J.A. Nonclinical studies addressing the mechanism of action of trastuzumab (herceptin). Semin. Oncol. 1999, 26, 60-70.
-
(1999)
Semin. Oncol
, vol.26
, pp. 60-70
-
-
Sliwkowski, M.X.1
Lofgren, J.A.2
Lewis, G.D.3
Hotaling, T.E.4
Fendly, B.M.5
Fox, J.A.6
-
98
-
-
84857601768
-
Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab
-
Lenihan, D.; Suter, T.; Brammer, M.; Neate, C.; Ross, G.; Baselga, J. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann. Oncol. 2012, 23, 791-800.
-
(2012)
Ann. Oncol
, vol.23
, pp. 791-800
-
-
Lenihan, D.1
Suter, T.2
Brammer, M.3
Neate, C.4
Ross, G.5
Baselga, J.6
-
99
-
-
47249137423
-
Activation of ampk is necessary for killing cancer cells and sparing cardiac cells
-
Shell, S.A.; Lyass, L.; Trusk, P.B.; Pry, K.J.; Wappel, R.L.; Bacus, S.S. Activation of ampk is necessary for killing cancer cells and sparing cardiac cells. Cell Cycle 2008, 7, 1769-1775.
-
(2008)
Cell Cycle
, vol.7
, pp. 1769-1775
-
-
Shell, S.A.1
Lyass, L.2
Trusk, P.B.3
Pry, K.J.4
Wappel, R.L.5
Bacus, S.S.6
-
100
-
-
34547537264
-
Activation of amp-activated protein kinase by human egf receptor 2/egf receptor tyrosine kinase inhibitor protects cardiac cells
-
Spector, N.L.; Yarden, Y.; Smith, B.; Lyass, L.; Trusk, P.; Pry, K.; Hill, J.E.; Xia, W.; Seger, R.; Bacus, S.S. Activation of amp-activated protein kinase by human egf receptor 2/egf receptor tyrosine kinase inhibitor protects cardiac cells. Proc. Natl. Acad. Sci. USA 2007, 104, 10607-10612.
-
(2007)
Proc. Natl. Acad. Sci. USA
, vol.104
, pp. 10607-10612
-
-
Spector, N.L.1
Yarden, Y.2
Smith, B.3
Lyass, L.4
Trusk, P.5
Pry, K.6
Hill, J.E.7
Xia, W.8
Seger, R.9
Bacus, S.S.10
-
101
-
-
79959923451
-
Targeting erbb3: The new rtk(id) on the prostate cancer block
-
Jathal, M.K.; Chen, L.; Mudryj, M.; Ghosh, P.M. Targeting erbb3: The new rtk(id) on the prostate cancer block. Immun. Endocr. Metab. Agents Med. Chem. 2011, 11, 131-149.
-
(2011)
Immun. Endocr. Metab. Agents Med. Chem
, vol.11
, pp. 131-149
-
-
Jathal, M.K.1
Chen, L.2
Mudryj, M.3
Ghosh, P.M.4
-
102
-
-
84859409756
-
Antitumor activity of a novel bispecific antibody that targets the erbb2/erbb3 oncogenic unit and inhibits heregulin-induced activation of erbb3
-
doi:10.1158/1535-7163.MCT-11-0820
-
McDonagh, C.F.; Huhalov, A.; Harms, B.D.; Adams, S.; Paragas, V.; Oyama, S.; Zhang, B.; Luus, L.; Overland, R.; Nguyen, S. et al. Antitumor activity of a novel bispecific antibody that targets the erbb2/erbb3 oncogenic unit and inhibits heregulin-induced activation of erbb3. Mol. Cancer Ther. 2012, doi:10.1158/1535-7163.MCT-11-0820.
-
(2012)
Mol. Cancer Ther
-
-
McDonagh, C.F.1
Huhalov, A.2
Harms, B.D.3
Adams, S.4
Paragas, V.5
Oyama, S.6
Zhang, B.7
Luus, L.8
Overland, R.9
Nguyen, S.10
-
103
-
-
77953343321
-
Pertuzumab for the treatment of ovarian cancer
-
Langdon, S.P.; Faratian, D.; Nagumo, Y.; Mullen, P.; Harrison, D.J. Pertuzumab for the treatment of ovarian cancer. Exp. Opin. Biol. Ther. 2010, 10, 1113-1120.
-
(2010)
Exp. Opin. Biol. Ther
, vol.10
, pp. 1113-1120
-
-
Langdon, S.P.1
Faratian, D.2
Nagumo, Y.3
Mullen, P.4
Harrison, D.J.5
|